Steminent Biotherapeutics Inc. (7729) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Steminent Biotherapeutics Inc. stock TWD 144, price TWD 174, upside -17.5%, quality 31 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
11‑month range 40.90 TWD – 232.00 TWD · fair‑value band 94.80 TWD – 179.40 TWD · the 174.00 TWD price screens above the 143.57 TWD fair value. As of Oct 28, 2026.
Follow Steminent Biotherapeutics in your weekly email
Every Wednesday you see whether Steminent Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States.
Show moreShow less
It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke.
The company was founded in 2009 and is based in Taipei, Taiwan.
Stock analysis
Steminent Biotherapeutics Inc. (7729) currently trades at 174.00 TWD, while our model-based Fair Value estimate is 143.57 TWD, 17.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 94.80 TWD (bear) to 179.40 TWD (bull), the price of 174.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Steminent Biotherapeutics Inc. reported revenue of 0 TWD in FY2024 versus 51.5M TWD in FY2020. Reported net income was −174M TWD in FY2025.
Key figures
Market cap 15.9B TWD (≈ $487M) Small · EPS (TTM) −2.96 TWD · Return on equity −31.7% · Return on assets (EBIT) −30.6% · Free cash flow −140M TWD · Net cash 142M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 325% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −17%, 7729 screens richer than that median.
Fair Value models
Bear94.80 TWDFair Value 143.57 TWDBull179.40 TWD
Price 174.00 TWD · Upside -17.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)111.53 TWD168.91 TWD211.06 TWD52
All 1 models by family
Asset-Based
NCAV (Graham)111.53 TWD168.91 TWD211.06 TWD52
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+48.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−73.7%
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−83.5% (2020) → −13,970.1% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Steminent Biotherapeutics Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 599 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside−17.5% · Above median
Profitability
Return on assets−24.9% · Below median
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Steminent Biotherapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/7729
Frequently asked questions
Is Steminent Biotherapeutics Inc. (7729) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 143.57 TWD versus a price of 174.00 TWD, about −17% upside (overvalued).
What is the fair value of 7729?
Our model-based fair value for Steminent Biotherapeutics Inc. is 143.57 TWD (as of Oct 28, 2026), built from audited fundamentals. The current price: 174.00 TWD.
What is the quality score of 7729?
Steminent Biotherapeutics Inc. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Steminent Biotherapeutics Inc. (7729)?
Our model-based price target is the fair value of 143.57 TWD (as of Oct 28, 2026) from 1 valuation models. Cautious scenario 94.80 TWD, optimistic scenario 179.40 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Steminent Biotherapeutics Inc. stock forecast for 2026?
Our models put fair value at 143.57 TWD, about −17% upside versus a price of 174.00 TWD (overvalued). Cautious scenario 94.80 TWD, optimistic scenario 179.40 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Steminent Biotherapeutics Inc. (7729)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Steminent Biotherapeutics Inc. it is 143.57 TWD per share (as of Oct 28, 2026), against a price of 174.00 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Steminent Biotherapeutics Inc. stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 7729 trades above its calculated fair value: price 174.00 TWD, fair value 143.57 TWD, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7729?
No. The price is what the market pays today (174.00 TWD); the fair value is what the company's own numbers justify (143.57 TWD). For Steminent Biotherapeutics Inc. the two are 30.43 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Steminent Biotherapeutics Inc. worth?
The market values Steminent Biotherapeutics Inc. at about 15.9B TWD (market capitalisation, as of Oct 28, 2026). Per share that is 174.00 TWD; our models calculate a fair value of 143.57 TWD per share.
What do the bullish and bearish scenarios say about 7729?
Our models span a range for Steminent Biotherapeutics Inc.: cautious scenario 94.80 TWD, base 143.57 TWD, optimistic 179.40 TWD per share (as of Oct 28, 2026, price 174.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Steminent Biotherapeutics Inc. (7729)?
Balance-sheet figures for Steminent Biotherapeutics Inc. (as of Oct 28, 2026): return on equity −31.7%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 7729 from its 52-week high?
Steminent Biotherapeutics Inc. trades at 174.00 TWD, about 25% below its 52-week high of 232.00 TWD and 325% above the low of 40.90 TWD (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 143.57 TWD is for.
Which stocks are comparable to Steminent Biotherapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Steminent Biotherapeutics Inc. stock attractive at the current price?
The data as of Oct 28, 2026: price 174.00 TWD, calculated fair value 143.57 TWD (−17%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7729 calculated?
We run Steminent Biotherapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 143.57 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Steminent Biotherapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Steminent Biotherapeutics Inc. (7729)?
The closing price on Oct 28, 2026 was 174.00 TWD. Our model-based fair value is 143.57 TWD, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Steminent Biotherapeutics Inc. right now?
Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (94.80 TWD to 179.40 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Steminent Biotherapeutics Inc.
How large is the market capitalisation of Steminent Biotherapeutics Inc. (7729)?
The market capitalisation of Steminent Biotherapeutics Inc. is 15.9B TWD (≈ $487M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Steminent Biotherapeutics Inc. (7729)?
Earnings per share at Steminent Biotherapeutics Inc. are −2.96 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Steminent Biotherapeutics Inc. (7729)?
The return on equity (ROE) of Steminent Biotherapeutics Inc. is −31.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Steminent Biotherapeutics Inc. (7729)?
On an EBIT basis the return on assets of Steminent Biotherapeutics Inc. is −30.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Steminent Biotherapeutics Inc. (7729) generate?
The free cash flow of Steminent Biotherapeutics Inc. is −140M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Steminent Biotherapeutics Inc. (7729) hold?
Steminent Biotherapeutics Inc. holds more cash than debt, 142M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Steminent Biotherapeutics Inc. in the live analysis
One click puts Steminent Biotherapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 28, 2026